ABSTRACT
We present a compact silicon photonic crystal spectrometer with a footprint of 740 × 9 µm2 and excellent wavelength resolution (â¼0.01 nm at single and <0.03 nm at multiple wavelength operation) across a telecom bandwidth of 10 nm. Although our design targets a wavelength resolution of 1.6 nm, within the current state-of-the-art fabrication precision of 2 nm, we achieve a resolution that exceeds these limits. This enhanced resolution is made possible by leveraging the random localization of light within the device.
ABSTRACT
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
ABSTRACT
The ability to monitor subtle changes in vital and arterial signals using flexible devices attached to the human skin can be valuable for the detection of various health conditions such as cardiovascular disease. Conventional Si device technologies are being utilised in traditional clinical systems; however, its fabrication is not easy owing to the difficulties in adapting to conventional processes. Here, we present the development of a fully printed, wearable, ferroelectric-polymer vital sensor for monitoring the human pulse wave/rate on the skin. This vital sensor is compact, thin, sufficiently flexible, and conforms to the skin while providing high pressure sensitivity, fast response time, superior operational stability, and excellent mechanical fatigue properties. Moreover, the vital sensor is connected to a communication amplifier circuit for monitoring the pulse waves with a wireless sensing system. This sensor system can realise the development of new healthcare devices for wearable sensor applications.
Subject(s)
Heart Rate/physiology , Monitoring, Physiologic/instrumentation , Remote Sensing Technology/instrumentation , Cardiovascular Diseases/diagnosis , Early Diagnosis , Humans , Printing, Three-Dimensional , Wearable Electronic Devices , Wireless TechnologyABSTRACT
Epidemiologic studies have shown that a low level of high-density lipoprotein (HDL) cholesterol is a risk factor for cardiovascular diseases. The purpose of this study was to determine the contribution of isolated low HDL cholesterol to endothelial function. Thirty-nine subjects with low HDL cholesterol who had no other cardiovascular risk factors were selected from the 5,417 participants from our population. We evaluated flow-mediated vasodilation (FMD) before and after 4 wk of treatment with the HMG-CoA reductase inhibitor pravastatin in 29 of the 39 subjects with isolated low HDL cholesterol. FMD was lower in the low-HDL-cholesterol group (n = 29) than in the control group (n = 29), whereas NTG-induced vasodilation was similar in the two groups. Pravastatin increased HDL cholesterol, urinary excretion of nitrite/nitrate, circulating levels of progenitor cells, and cell migration response to vascular endothelial growth factor in 15 subjects with low HDL cholesterol but not in 14 placebo control subjects. FMD increased in the pravastatin treatment group but not in the control group. NTG-induced vasodilation was similar before and after 4 wk of treatment in the two groups. Multiple regression analysis revealed that changes in HDL cholesterol, the number of progenitor cells, and migration of progenitor cells were independent predictors of augmentation of FMD with pravastatin. These findings suggest that low HDL cholesterol is an independent risk factor for endothelial dysfunction and that pravastatin improves endothelial function in individuals with isolated low HDL cholesterol through, at least in part, an increase in circulating progenitor cells.
Subject(s)
Cardiovascular Diseases/physiopathology , Cholesterol, HDL/blood , Endothelium, Vascular/physiology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Pravastatin/pharmacology , Stem Cells/drug effects , Adult , Aged , Aged, 80 and over , Anticholesteremic Agents/pharmacology , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/prevention & control , Case-Control Studies , Cholesterol, HDL/drug effects , Cohort Studies , Endothelium, Vascular/drug effects , Female , Humans , Male , Middle Aged , Nitric Oxide/metabolism , Nitroglycerin , Reference Values , Risk Factors , Statistics, Nonparametric , Stem Cells/physiology , Vascular Endothelial Growth Factor A/drug effects , Vascular Endothelial Growth Factor A/physiology , Vasodilation/drug effects , Vasodilation/physiology , Vasodilator Agents , Young AdultABSTRACT
BACKGROUND: Hypercholesterolemia enhances platelet aggregability. Statins have beneficial effects on cardiovascular events. The purpose of this study is to investigate whether statins inhibit platelet aggregation and, if so, the mechanisms. METHODS AND RESULTS: Twelve patients with hypercholesterolemia were prospectively randomized in a crossover design to receive either fluvastatin (20 mg/d) or colestimide (3000 mg/d) for 12 weeks. The subjects were switched to the opposite arm for additional 12 weeks. Before and after first and second treatments, experiments were performed. Eleven age-matched volunteers with normal lipid profiles served as controls. ADP-induced platelet aggregation, platelet-derive nitric oxide (PDNO) release, intraplatelet levels of GSH and GSSG, and intraplatelet nitrotyrosine production during platelet aggregation were measured. Fluvastatin and colestimide equally lowered total and low density lipoprotein cholesterol levels in hypercholesterolemia. Platelet aggregation was greater in hypercholesterolemia than in normocholesterolemia before treatment and was altered by fluvastatin. PDNO release, intraplatelet glutathione level, and GSH/GSSG ratio were lower in hypercholesterolemia than in normocholesterolemia before treatment and were increased by fluvastatin. Intraplatelet nitrotyrosine formation was greater in hypercholesterolemia than in normocholesterolemia, and decreased by fluvastatin. Colestimide did not have such effects. In vitro application of fluvastatin dose-dependently inhibited platelet aggregation. Furthermore, in vitro application of fluvastatin dose-dependently inhibited platelet nitrotyrosine expressions and the inhibitory effects by fluvastatin were reversed by preincubation with geranylgeranylpyrophosphate. CONCLUSIONS: Fluvastatin altered platelet aggregability in hypercholesterolemic patients in a cholesterol-lowering independent manner, which was partly mediated by the improvement of intraplatelet redox imbalance.
Subject(s)
Anion Exchange Resins/therapeutic use , Blood Platelets/drug effects , Epichlorohydrin/therapeutic use , Fatty Acids, Monounsaturated/therapeutic use , Hydroxymethylglutaryl CoA Reductases/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/drug therapy , Imidazoles/therapeutic use , Indoles/therapeutic use , Platelet Aggregation/drug effects , Resins, Synthetic/therapeutic use , Adult , Anion Exchange Resins/pharmacology , Blood Platelets/metabolism , Cholesterol/blood , Cross-Over Studies , Dose-Response Relationship, Drug , Epichlorohydrin/pharmacology , Fatty Acids, Monounsaturated/pharmacology , Female , Fluvastatin , Glutathione/metabolism , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hypercholesterolemia/blood , Hypercholesterolemia/metabolism , Imidazoles/pharmacology , Indoles/pharmacology , Male , Middle Aged , Nitric Oxide/metabolism , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Polyisoprenyl Phosphates/pharmacology , Prospective Studies , Resins, Synthetic/pharmacology , Treatment Outcome , Triglycerides/blood , Tyrosine/analogs & derivatives , Tyrosine/metabolismABSTRACT
OBJECTIVES: To examine whether polymorphonuclear leukocytes (PMNs) in hypercholesterolemia (HC) are activated to generate large amount of superoxide in vivo and hence impair endothelial function and, if so, whether statins, which possess anti-inflammatory properties, may restore PMN-mediated endothelial dysfunction. METHODS AND RESULTS: At baseline, subjects with HC showed impaired endothelial function (P<0.001), estimated by flow-mediated vasodilation of the brachial artery, and increased susceptibility of low-density lipoprotein (LDL) to oxidation (P<0.0001) compared with control subjects. PMNs obtained from HC produced greater amount of superoxide (P<0.0001), showed higher adhesiveness to cultured endothelial cells (HUVECs) (P<0.0001), and impaired endothelial nitric oxide synthase (eNOS) Ser1177 phosphorylation of HUVECs compared with controls (P<0.001). Crossover administration of fluvastatin or colestimide for 3 months lowered LDL to the same levels (P<0.001 for both). Endothelial function was restored (P<0.0001). LDL oxidation (P<0.0001) and superoxide release from PMNs (P<0.0001) were diminished only in fluvastatin but not in colestimide arm. Fluvastatin attenuated PMN adhesion to HUVECs (P<0.0001) and restored eNOS Ser1177 phosphorylation of HUVECs (P<0.001). CONCLUSIONS: Statins may improve endothelial function at least in part by inactivating neutrophils independently of LDL reduction. Our results raise a novel concept that polymorphonuclear leukocytes may attack endothelia and play a pivotal role in the pathogenesis of atherosclerosis.